The publication of this infographic was sponsored by Deciphera Pharmaceuticals, LLC.
The European Society for Medical Oncology (ESMO) guidelines recommend life-long systemic tyrosine kinase inhibitor (TKI) therapies for advanced gastrointestinal stromal tumours (GIST), in order to improve patient outcomes.1 Toxicity management and tolerability during long-term treatment can be a challenge for some patients as severe and/or unmanaged toxicities may impact QoL and can lead to a lack of compliance, treatment interruption, or treatment discontinuation.1,2 This infographic summarises key considerations when treating advanced GIST.
Topics covered include:
- ESMO Guidelines summary for long-life systemic TKI for advanced GIST;1
- balancing radiologic progression and clinical benefits when evaluating treatment management and change of lines of treatment;1 and
- importance of multidisciplinary treatment planning for advanced GIST.1
For healthcare professionals only.
DCPH-P01778 | February 2025
References:
1. Casali PG et al. Ann Oncol. 2022;33(1):20-33.
2. Brackert S, Polson K. J Adv Pract Oncol. 2023;14(4):317-28.
